Despite the high disease burden of dengue virus, there is no approved antiviral treatment or broadly applicable vaccine to treat or prevent dengue virus infection. In the last decade, many antiviral compounds have been identified but only few have been further evaluated in pre-clinical or clinical trials. This review will give an overview of the direct-acting and host-directed antivirals identified to date. Furthermore, important parameters for further development that is, drug properties including efficacy, specificity and stability, pre-clinical animal testing, and combinational drug therapy will be discussed
Nucleoside analogs represent the largest class of antiviral agent and have been actively pursued for...
Introduction: Almost half the global population is estimated to be at risk of contracting dengue inf...
Dengue, West Nile and Zika viruses are vector-borne flaviviruses responsible for numerous disease ou...
Despite the high disease burden of dengue virus, there is no approved antiviral treatment or broadly...
Dengue fever is caused by infections with dengue virus, the most prevalent mosquito-borne viral path...
Dengue virus is an emerging human pathogen that poses a huge public health burden by infecting annua...
Dengue is the most important arthropod-borne viral disease of humans, with more than half of the glo...
Dengue is a mosquito-borne viral disease caused by four antigenically distinct serotypes of Dengue V...
Dengue is the most common arboviral disease of humans. There is an unmet need for a therapeutic inte...
Dengue is the most common arboviral disease of humans. There is an unmet need for a therapeutic inte...
Dengue is the most common arboviral disease of humans. There is an unmet need for a therapeutic inte...
Dengue fever, a reemerging disease, is putting nearly 2.5 billion people at risk worldwide. The numb...
Approximately 100–400 million people from more than 100 countries in the tropical and subtropical wo...
AbstractDengue is a common pathogenic disease often proving fatal, more commonly affecting the tropi...
Mosquito-borne flavivirus infections affect approximately 400 million people worldwide each year and...
Nucleoside analogs represent the largest class of antiviral agent and have been actively pursued for...
Introduction: Almost half the global population is estimated to be at risk of contracting dengue inf...
Dengue, West Nile and Zika viruses are vector-borne flaviviruses responsible for numerous disease ou...
Despite the high disease burden of dengue virus, there is no approved antiviral treatment or broadly...
Dengue fever is caused by infections with dengue virus, the most prevalent mosquito-borne viral path...
Dengue virus is an emerging human pathogen that poses a huge public health burden by infecting annua...
Dengue is the most important arthropod-borne viral disease of humans, with more than half of the glo...
Dengue is a mosquito-borne viral disease caused by four antigenically distinct serotypes of Dengue V...
Dengue is the most common arboviral disease of humans. There is an unmet need for a therapeutic inte...
Dengue is the most common arboviral disease of humans. There is an unmet need for a therapeutic inte...
Dengue is the most common arboviral disease of humans. There is an unmet need for a therapeutic inte...
Dengue fever, a reemerging disease, is putting nearly 2.5 billion people at risk worldwide. The numb...
Approximately 100–400 million people from more than 100 countries in the tropical and subtropical wo...
AbstractDengue is a common pathogenic disease often proving fatal, more commonly affecting the tropi...
Mosquito-borne flavivirus infections affect approximately 400 million people worldwide each year and...
Nucleoside analogs represent the largest class of antiviral agent and have been actively pursued for...
Introduction: Almost half the global population is estimated to be at risk of contracting dengue inf...
Dengue, West Nile and Zika viruses are vector-borne flaviviruses responsible for numerous disease ou...